Omeros Corporation
201 Elliott Avenue West
Seattle
Washington
98119
United States
Tel: 206.676.5000
Fax: 206.676.5005
Website: https://www.omeros.com/
Email: hr@omeros.com
About Omeros Corporation
At Omeros, we are proud of our innovative and cutting-edge science. Our world-class team has achieved scientific advances that no other group has been able to accomplish, delivering wholly new classes of therapeutics to benefit patients. We let science lead the way.
From our foundation of groundbreaking science, we continue to build and advance a deep and diverse pipeline of small-molecule and protein therapeutics. We are not interested in developing “me-too” products; instead, we are focused on tackling challenging diseases and disorders with significant unmet medical needs. The result is an exciting pipeline of first-in-class drugs with new mechanisms of action that target previously untapped receptors and enzymes.
The Omeros team is exceptionally talented, passionate, collaborative and diverse. We hire smart, creative and hard-working people who want to play a meaningful part in building a preeminent biopharmaceutical company. We come from all corners of the globe, bringing unique abilities and experiences together to provide hope to patients and their families.
418 articles with Omeros Corporation
-
Omeros Announces Agreement to Sell OMIDRIA® Franchise to Rayner Surgical in a Transaction Valued in Excess of $1 Billion
12/2/2021
Omeros Announces Agreement to Sell OMIDRIA ® Franchise to Rayner Surgical in a Transaction Valued in Excess of $1 Billion.
-
Omeros Corporation Reports Third Quarter 2021 Financial Results
11/9/2021
Omeros Corporation announced recent highlights and developments as well as financial results for the third quarter ended September 30, 2021, which include:
-
Omeros Announces Results From Nearly Three-Year Follow-up of Patients in Phase 2 IgA Nephropathy Trial
11/5/2021
Omeros Corporation (Nasdaq: OMER) today announced results of long-term follow-up from the Phase 2 clinical trial evaluating its MASP-2 inhibitor narsoplimab in patients with IgA nephropathy.
-
Omeros’ Narsoplimab Stabilized Kidney Function and Reduced Urinary Complement Proteins in a Patient with IgA Vasculitis
11/5/2021
Omeros Corporation (Nasdaq: OMER) today announced that the first report on urinary complement levels in kidney disease was presented yesterday at the Annual Meeting of the American Society of Nephrology.
-
Omeros Corporation to Announce Third Quarter Financial Results on November 9, 2021
11/4/2021
Omeros Corporation (NASDAQ: OMER) today announced that the company will issue its third quarter financial results for the period ended September 30, 2021, on Tuesday, November 9, 2021, after the market closes.
-
Omeros Receives Complete Response Letter from FDA for Biologics License Application for Narsoplimab in the Treatment of HSCT-TMA
10/18/2021
Omeros Corporation announced that the company received a Complete Response Letter from the U.S. Food and Drug Administration regarding its Biologics License Application for narsoplimab in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy.
-
Omeros Corporation shares were down in premarket trading after the company received a CRL for its experimental hematopoietic stem cell transplant-associated thrombotic microangiopathy treatment.
-
The U.S. Food and Drug Administration has a few PDUFA dates on its calendar for this week. Here’s a look.
-
Omeros Corporation Reports Second Quarter 2021 Financial Results
8/9/2021
Omeros Corporation (Nasdaq: OMER), today announced recent highlights and developments as well as financial results for the second quarter ended June 30, 2021.
-
Omeros Corporation to Announce Second Quarter Financial Results on August 9, 2021
8/3/2021
Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its second quarter financial results for the period ended June 30, 2021, on Monday, August 9, 2021, after the market closes. Omeros management will host a conference call and webcast that day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results as well as recent developments and highlights.
-
Omeros’ Narsoplimab Pivotal Trial Data Shared in Oral Presentation at 2021 Annual Congress of the European Hematology Association
6/14/2021
Omeros Corporation (Nasdaq: OMER) today announced that data on organ function improvement from its pivotal trial of narsoplimab were shared during an oral presentation at the virtual edition of the 26th Congress of the European Hematology Association (EHA).
-
Omeros Announces Publication Detailing the Mechanism of Action of PDE7 In Nicotine Addiction
6/10/2021
Omeros Corporation today announced publication of the article “Selective inhibition of phosphodiesterase 7 enzymes reduces motivation for nicotine use through modulation of mesolimbic dopaminergic transmission” in the peer-reviewed Journal of Neuroscience.
-
Omeros Announces Preliminary Results from Phase 1 Clinical Trial of OMS906
6/9/2021
Omeros Corporation today announced preliminary results from the Phase 1 clinical trial of its MASP-3 inhibitor OMS906.
-
Omeros to Present at the BofA 2021 Napa BioPharma Virtual Conference
6/9/2021
Omeros Corporation (Nasdaq: OMER), today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, will present at the BofA 2021 Napa BioPharma Virtual Conference next week.
-
Omeros Announces Extension of FDA Review Period for Narsoplimab in HSCT-TMA
5/20/2021
Omeros Corporation today reported that the U.S. Food and Drug Administration (FDA) will require additional time to review the Biologics License Application (BLA) for narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA). The new Prescription Drug User Fee Act (PDUFA) target action date is October 17, 2021.
-
Omeros’ Narsoplimab Pivotal Trial Data to Be Shared as an Oral Presentation at the European Hematology Association Congress
5/13/2021
Omeros Corporation (Nasdaq: OMER) today announced that data on organ function improvement from Omeros’ pivotal trial of narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) will be shared as an oral presentation at the 2021 European Hematology Association (EHA) Virtual Congress.
-
Omeros Corporation Reports First Quarter 2021 Financial Results
5/10/2021
Omeros Corporation, a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, immunologic diseases and central nervous system disorders, announced recent highlights and developments as well as financial results for the first quarter ended March 31, 2021, which include:
-
Omeros Corporation to Announce First Quarter Financial Results on May 10, 2021
5/5/2021
Omeros Corporation, announced that the company will issue its first quarter financial results for the period ended March 31, 2021, on Monday, May 10, 2021, after the market closes.
-
Omeros Corporation Announces Approval of ICD-10 Codes for HSCT-TMA Diagnosis and for Narsoplimab Administration
5/4/2021
Omeros Corporation announced that the Centers for Disease Control and Prevention has approved an International Classification of Diseases diagnosis code, M31.11 – hematopoietic stem cell transplantation-associated thrombotic microangiopathy.
-
Omeros and Quantum Leap Announce First Patients Dosed with Narsoplimab in the I-SPY COVID-19 Trial
3/23/2021
-- Adaptive Platform Trial is Evaluating Drugs and Investigational Products in the Treatment of Critically Ill COVID-19 Patients --